Stock comparison
NeuroPace
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
NPCE
NeuroPace
Market cap
$536.42M
Sector
Healthcare
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | NPCE | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 30F | 64C | RMD |
| Benjamin Graham | 55C | 67B | RMD |
| Philip Fisher | 42D | 67B | RMD |
| Peter Lynch | 66B | 50C | NPCE |
| Joel Greenblatt | 0F | 39D | RMD |
| Charlie Munger | 28F | 61C | RMD |
| Terry Smith | 24F | 65B | RMD |
Side-by-side metrics
| Metric | NPCE | RMD |
|---|---|---|
| Market cap | $536.42M | $29.57B |
| P/E (TTM) | - | 19.6x |
| EV/EBIT | - | 17.1x |
| ROIC (TTM) | -19.74% | 19.63% |
| Gross margin | 78.29% | 61.69% |
| Net margin | -14.95% | 27.44% |
| Revenue CAGR 5y | 21.97% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 4.9x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
NPCE leads on
- P/E (TTM)-vs 19.6x+155%
- EV/EBIT-vs 17.1x+147%
- Revenue CAGR 5y21.97%vs 12.64%+42%
- Gross margin78.29%vs 61.69%+21%
RMD leads on
- ROIC (TTM)19.63%vs -19.74%+199%
- Net margin27.44%vs -14.95%+154%
- Dividend yield1.14%vs 0.0%+100%
- Market cap$29.57Bvs $536.42M+98%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.